Relationship between EGFR expression, EGFR mutation status, and the efficacy of chemotherapy plus cetuximab in FLEX study patients with advanced non-small-cell lung cancer

Journal of Thoracic Oncology

Volumn 9, Issue 5, 2014, Pages 717-724

  Douillard, Jean Yves ^a   Pirker, Robert ^b   O'Byrne, Kenneth J ^c   Kerr, Keith M ^d   Störkel, Stephan ^e   Von Heydebreck, Anja ^f   Grote, Hans Jürgen ^f   Celik, Ilhan ^f   Shepherd, Frances A ^g  

^a CENTRE RENÉ GAUDUCHEAU   (France)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c ST JAMES S HOSPITAL   (Ireland)

^d ABERDEEN ROYAL INFIRMARY   (United Kingdom)

^e UNIVERSITY OF WITTEN HERDECKE   (Germany)

^f MERCK KGAA   (Germany)

^g UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

Advanced NSCLC; Cetuximab; Chemotherapy; EGFR expression; EGFR mutation; FLEX

Indexed keywords

CETUXIMAB; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; NAVELBINE; ANTINEOPLASTIC AGENT; EGFR PROTEIN, HUMAN; MONOCLONAL ANTIBODY; VINBLASTINE;

ADD ON THERAPY; ADVANCED CANCER; ARTICLE; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; CLINICAL ASSESSMENT; CORRELATION ANALYSIS; DRUG EFFICACY; EGFR GENE; EXON; GENE; GENE DELETION; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTENTION TO TREAT ANALYSIS; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PHARMACOGENOMICS; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; SURVIVAL TIME; TREATMENT OUTCOME; TREATMENT RESPONSE; ANALOGS AND DERIVATIVES; CARCINOMA, NON-SMALL-CELL LUNG; CHEMISTRY; CLINICAL TRIAL; DISEASE COURSE; DISEASE FREE SURVIVAL; GENETICS; LUNG NEOPLASMS; NUCLEOTIDE SEQUENCE; SURVIVAL RATE; TIME;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BASE SEQUENCE; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DNA MUTATIONAL ANALYSIS; EXONS; HUMANS; LUNG NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SEQUENCE DELETION; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME; VINBLASTINE;

EID: 84899475126     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0000000000000141     Document Type: Article

References (35)

1. Pirker R Pereira JR Szczesna A et al.; FLEX Study Team. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet 2009;373:1525-1531.
2. Pirker R Pereira JR von Pawel J et al. EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study. Lancet Oncol 2012;13:33-42.
3. Sharma SV Bell DW Settleman J Haber DA. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 2007;7:169-181.
4. Eck MJ Yun CH. Structural and mechanistic underpinnings of the differential drug sensitivity of EGFR mutations in non-small cell lung cancer. Biochim Biophys Acta 2010;1804:559-566.
5. Gazdar AF. Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors. Oncogene 2009;28(Suppl 1):S24-S31.
6. Pao W Chmielecki J. Rational biologically based treatment of EGFR-mutant non-small-cell lung cancer. Nat Rev Cancer 2010;10:760-774.
7. Yasuda H Kobayashi S Costa DB. EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications. Lancet Oncol 2012;13:e23-e31.
8. Su KY Chen HY Li KC et al. Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer. J Clin Oncol 2012;30:433-440.
9. Suda K Onozato R Yatabe Y Mitsudomi T. EGFR T790M mutation: a double role in lung cancer cell survival J Thorac Oncol 2009;4:1-4.
10. Gatzemeier U Pluzanska A Szczesna A et al. Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial. J Clin Oncol 2007;25:1545-1552.
11. Giaccone G Herbst RS Manegold C et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT J Clin Oncol 2004;22:777-784.
12. Herbst RS Giaccone G Schiller JH et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT J Clin Oncol 2004;22:785-794.
13. Herbst RS Prager D Hermann R et al.; TRIBUTE Investigator Group. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2005;23:5892-5899.
14. Mitsudomi T Morita S Yatabe Y et al.; West Japan Oncology Group. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label randomised phase 3 trial. Lancet Oncol 2010;11:121-128.
15. Mok TS Wu YL Thongprasert S et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009;361:947-957.
16. Rosell R Carcereny E Gervais R et al.; Spanish Lung Cancer Group in collaboration with Groupe Français de Pneumo-Cancé rologie and Associazione Italiana Oncologia Toracica. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre open-label randomised phase 3 trial. Lancet Oncol 2012;13:239-246.
17. Zhou C Wu YL Chen G et al. Erlotinib versus chemotherapy as firstline treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL CTONG-0802): a multicentre open-label randomised phase 3 study. Lancet Oncol 2011;12:735-742.
18. Bria E Milella M Cuppone F et al. Outcome of advanced NSCLC patients harboring sensitizing EGFR mutations randomized to EGFR tyrosine kinase inhibitors or chemotherapy as first-line treatment: a meta-analysis. Ann Oncol 2011;22:2277-2285.
19. Sequist LV Yang JC Yamamoto N et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol 2013;31:3327-3334.
20. Li S Schmitz KR Jeffrey PD Wiltzius JJ Kussie P Ferguson KM. Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. Cancer Cell 2005;7:301-311.
21. O'Byrne KJ Gatzemeier U Bondarenko I et al. Molecular biomarkers in non-small-cell lung cancer: a retrospective analysis of data from the phase 3 FLEX study. Lancet Oncol 2011;12:795-805.
22. Oxnard GR Miller VA Robson ME et al. Screening for germline EGFR T790M mutations through lung cancer genotyping. J Thorac Oncol 2012;7:1049-1052.
23. Greaves M Maley CC. Clonal evolution in cancer. Nature 2012;481:306-313.
24. Gandhi L Jänne PA. Crizotinib for ALK-rearranged non-small cell lung cancer: a new targeted therapy for a new target. Clin Cancer Res 2012;18:3737-3742.
25. Lorusso V Silvestris N Marech I. TORCH study: how much longer should we continue to use erlotinib in unselected patients with non-small-cell lung cancer J Clin Oncol 2013;31:288-289.
26. Wu JY Yu CJ Chang YC Yang CH Shih JY Yang PC. Effectiveness of tyrosine kinase inhibitors on "uncommon" epidermal growth factor receptor mutations of unknown clinical significance in non-small cell lung cancer. Clin Cancer Res 2011;17:3812-3821.
27. Liang Z Zhang J Zeng X Gao J Wu S Liu T. Relationship between EGFR expression copy number and mutation in lung adenocarcinomas. BMC Cancer 2010;10:376.
28. Pinter F Papay J Almasi A et al. Epidermal growth factor receptor (EGFR) high gene copy number and activating mutations in lung adenocarcinomas are not consistently accompanied by positivity for EGFR protein by standard IHC. J Mol Diagn 2008;10:160-168.
29. Cappuzzo F Hirsch FR Rossi E et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst 2005;97:643-655.
30. Tsao AS Tang XM Sabloff B et al. Clinicopathologic characteristics of the EGFR gene mutation in non-small cell lung cancer. J Thorac Oncol 2006;1:231-239.
31. Bell DW Lynch TJ Haserlat SM et al. Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials. J Clin Oncol 2005;23:8081-8092.
32. Eberhard DA Johnson BE Amler LC et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol 2005;23:5900-5909.
33. Kalikaki A Koutsopoulos A Hatzidaki D et al. Clinical outcome of patients with non-small cell lung cancer receiving front-line chemotherapy according to EGFR and K-RAS mutation status. Lung Cancer 2010;69:110-115.
34. Doody JF Wang Y Patel SN et al. Inhibitory activity of cetuximab on epidermal growth factor receptor mutations in non small cell lung cancers. Mol Cancer Ther 2007;6:2642-2651.
35. Redman MW Crowley JJ Herbst RS Hirsch FR Gandara DR. Design of a phase III clinical trial with prospective biomarker validation: SWOG S0819. Clin Cancer Res 2012;18:4004-4012.